SAN DIEGO, March 12, 2020 /PRNewswire/ -- Mesa Biotech, Inc., a privately-held, molecular diagnostic company that has developed an affordable, easy-to-use, point-of-care (POC) testing platform designed specifically for point-of-care infectious disease diagnosis, today announced it is receiving approximately $561,000 in funding from the U.S. Department of Health and Human Services (HHS); Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development, validation and FDA-Emergency Use Authorization (EUA) submission of its SARS-CoV-2 test. Mesa Biotech's proprietary PCR platform technology will enable healthcare providers to rapidly detect SARS-CoV-2 infection at the point-of-care with increased confidence, providing a definitive result within about 30 minutes. The Accula™ SARS-CoV-2 Test will utilize a nasopharyngeal swab and will be performed on Mesa Biotech's compact, easy-to-use, point-of-care molecular dock. The test will require only minimal sample preparation and no special technical training to perform. "Rapid and accurate diagnosis is critical in containing the spread of the SARS-CoV-2 virus," said Hong Cai, Co-founder and Chief Executive Officer of Mesa Biotech. "Our Accula system is uniquely positioned to address this need. We are pleased to partner with BARDA to accelerate the development of our SARS-CoV-2 test and make it available to healthcare professionals as quickly as possible." About Mesa Biotech, Inc. Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care. Mesa Biotech's Accula™ platform allows healthcare professionals to access actionable, molecular diagnostic information at the point-of-care with a rapid, easy-to-use, cost-effective solution. Mesa Biotech's Accula Flu A/Flu B and RSV tests have obtained CE Mark in the EU and 510(k) clearance and CLIA waiver from the U.S. FDA. For more information visit http://www.mesabiotech.com. View original content to download multimedia:http://www.prnewswire.com/news-releases/mesa-biotech-to-receive-funding-from-us-health-and-human-services-for-development-of-a-30-minute-molecular-pcr-point-of-care-sars-cov-2-test-301027048.html SOURCE Mesa Biotech, Inc.